Sequential re-rating: management describes the same offering landing bigger the second and third time around
The model's full reasoning — Q1 2024 call → NOWe need to determine if management describes that successive engagements of the same kind are coming in at progressively larger size. The question asks about a specific phenomenon: the unit size of the company's repeatable business escalating. We need to see if management conveys that the deals, orders, contracts, projects, customers, sites, or programs they are landing now are individually bigger, broader, or longer than before for the same offering. Let's scan the transcript for any such statements. The call covers Q1 2024 results. Management discusses various segments: U.S., Europe, Mexico. They talk about growth, key customer partnerships, operational excellence, etc. But do they mention that the size of individual deals or contracts is increasing? For example, do they say that new customer contracts are larger than previous ones? Or that they are winning bigger projects? Or that the scope of engagements is expanding? Looking at the transcript: Fabio Sandri mentions "key customer partnerships" and "growth of value-added offerings". He says "Case Ready increased its marketplace presence, given key customer growth supported by our differentiated offerings". That's about growth with customers, but not necessarily about the size of individual engagements. He mentions "our brands grew across Retail and foodservice" and "branded offerings rose double digits". That's about volume or revenue growth, not about unit size. In Europe, he says "the team secured additional business with several key customers in Retail" and "Efforts to further diversify our portfolio continue to gain traction as our brands grew faster than category averages." Again, that's about growth, not about larger individual deals. In Mexico, "key customer partnerships grew over 13% during the quarter." That's growth in partnerships, but not necessarily that each partnership is larger. There is no mention of "average order size", "larger contracts", "bigger projects", "expanded scope", "initial commitments are larger", etc. The discussion is about overall growth, volume, and profitability improvements. There is no comparison against the company's own past in terms of the size of individual engagements.
| Ticker | Company | Call | Date | Call grade |
|---|---|---|---|---|
| ASO | Academy Sports and Outdoors, Inc. | Q1 2024 | 2024-06-11 | C+ |
| AKYA | Akoya Biosciences, Inc. | Q2 2023 | 2023-08-07 | C+ |
| SPT | Sprout Social, Inc. | Q2 2023 | 2023-08-04 | B+ |
| SGRY | Surgery Partners, Inc. | Q2 2022 | 2022-08-02 | B+ |
| CYBR | CyberArk Software Ltd. | Q3 2021 | 2021-11-04 | B+ |
| ASAN | Asana, Inc. | Q2 2022 | 2021-09-01 | B+ |
| OWL | Blue Owl Capital Inc. | Q2 2021 | 2021-08-10 | B+ |
AKYA · Q2 2023 → YESThe question is: Does management describe that the company's SUCCESSIVE ENGAGEMENTS OF THE SAME KIND ARE COMING IN AT PROGRESSIVELY LARGER SIZE? YES The transcript shows management describing a clear pattern of escalating project sizes in the translational/clinical space. Brian notes a migration from exploratory studies (reasonable size) to larger retrospective studies and even larger retrospective-prospective ongoing clinical studies, with projects moving "further and further downstream.
ASAN · Q2 2022 → YESThe question is: Does management describe that the company's SUCCESSIVE ENGAGEMENTS OF THE SAME KIND ARE COMING IN AT PROGRESSIVELY LARGER SIZE? YES Management describes exactly this pattern. Dustin notes the company is “closing larger deals and expanding seats across departments and geographies quickly in large organizations,” and that the growth in the >$50k cohort “reflected an acceleration in our largest enterprise customers.
SGRY · Q2 2022 → YESThe question is: Does management describe that the company's SUCCESSIVE ENGAGEMENTS OF THE SAME KIND ARE COMING IN AT PROGRESSIVELY LARGER SIZE? YES The transcript shows management describing exactly this pattern for physician recruiting cohorts. Wayne notes that the 2022 cohorts are “no exception to this trend, bringing more cases with a higher overall net revenue per case than our 2021 cohorts did in the same period last year.